Siren L.L.C. Buys 161,544 Shares of Cellebrite DI Ltd. $CLBT

Siren L.L.C. boosted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 107.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 311,544 shares of the company’s stock after acquiring an additional 161,544 shares during the quarter. Siren L.L.C.’s holdings in Cellebrite DI were worth $4,293,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its stake in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $40,000. CWM LLC lifted its stake in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the period. First Horizon Corp raised its position in shares of Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the period. Finally, Vestcor Inc acquired a new stake in Cellebrite DI in the third quarter worth $70,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CLBT. DA Davidson initiated coverage on Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC dropped their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $14.06 on Friday. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The company has a market cap of $3.51 billion, a P/E ratio of 50.22, a P/E/G ratio of 1.76 and a beta of 1.17. The stock’s 50-day simple moving average is $14.16 and its 200 day simple moving average is $14.31.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 158,191 shares of company stock worth $2,479,438 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.